+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Kidney Disease Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • January 2024
  • Region: Global
  • The Business Research Company
  • ID: 5820069
The diabetic kidney disease market size has grown strongly in recent years. It will grow from $2.51 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to the early comprehension of diabetes complications, advancements in diagnostic techniques, the development of ACE inhibitors and ARBs, clinical trials and treatment protocols, and the establishment of guidelines and disease management protocols.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, the rising global incidence of diabetes, a focus on disease modification therapies, the adoption of telehealth and remote care, and changes in healthcare policy and reimbursement. Major trends in the forecast period include advancements in renal replacement therapies, a precision medicine approach, a focus on early detection and diagnosis, therapeutic advancements, and an emphasis on comorbidities management.

The anticipated surge in chronic kidney disease (CKD) cases is set to drive the expansion of the diabetic kidney disease market. CKD, a prolonged condition leading to gradual kidney function loss, manifests various complications such as high blood pressure, anemia, and bone diseases. Effective management of CKD necessitates diagnostic and treatment solutions, thereby stimulating growth in the diabetic kidney disease market. According to a 2021 report from the Centers for Disease Control and Prevention (CDC), over 37 million individuals were estimated to suffer from CKD in the USA, notably prevalent among adults aged 65 and above, with approximately 38% experiencing some form of kidney damage. This rise in CKD instances significantly contributes to the burgeoning diabetic kidney disease market.

The upsurge in healthcare expenditure is poised to propel the diabetic kidney disease market's growth trajectory. Healthcare expenditure denotes the total spending on healthcare-related goods and services within a specific period, often on a national or institutional scale. Increased healthcare investment facilitates the adoption of cutting-edge diagnostic technologies, enabling early and precise detection of diabetic kidney disease and prompt intervention. The 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022 projects an average annual growth of 5.1% in national health spending, reaching nearly $6.8 trillion by 2030. Notably, Medicare spending is forecasted to increase by 7.2% annually, and Medicaid spending by 5.6% annually from 2021 to 2030. Consequently, escalating healthcare expenditure serves as a driving force behind the diabetic kidney disease market's expansion.

Technological advancements emerge as a pivotal trend gaining traction in the diabetic kidney disease market. Companies within this sector embrace novel technologies to fortify their market standing. For instance, in August 2022, Bloom Diagnostics, a US-based organization specializing in diagnostics and healthcare devices, introduced the Bloom Kidney Test. Integrated with the Bloom Smart System, this diagnostic tool evaluates kidney health by measuring cystatin C levels - a reliable indicator of kidney function. Categorizing kidney function into three stages - normal, mildly decreased, and decreased - the Bloom Kidney Test leverages cloud-based algorithms and AI technology within the Bloom Smart System. This integration combines test outcomes with pertinent health data such as medical history, lifestyle, and patient symptoms, facilitating comprehensive analysis and management.

Leading companies in the diabetic kidney disease market are actively innovating by developing new products such as medications tailored for chronic kidney disease (CKD), aiming for wider customer reach, increased sales, and revenue growth. These medications for CKD primarily focus on symptom management, slowing disease progression, and addressing complications arising from impaired kidney function. For instance, Bayer AG, a Germany-based pharmaceutical company, introduced Kerendia in August 2022 - a medication specifically designed to manage CKD associated with diabetes. Kerendia stands out as a non-steroidal, selective mineralocorticoid receptor antagonist, uniquely tailored for individuals with chronic kidney disease linked to type-II diabetes. Offering a distinctive treatment approach, Kerendia holds promise in slowing CKD progression and reducing the risk of kidney failure in this susceptible patient group.

In January 2023, AstraZeneca, a UK-based biotech and pharmaceutical giant, finalized the acquisition of Cincor Pharma Inc. for an undisclosed sum. This strategic move strengthens AstraZeneca's cardiorenal pipeline by integrating CinCor's baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) aimed at lowering blood pressure in treatment-resistant hypertension. Cincor Pharma Inc., a US-based biopharmaceutical company, specializes in developing drugs for kidney disease management. AstraZeneca's acquisition bolsters its portfolio by incorporating innovative solutions such as baxdrostat, further solidifying its position in addressing cardiorenal complications and advancing therapeutic options for kidney disease management.

Major companies operating in the diabetic kidney disease market report are AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, Allergan Inc., Endo International Inc., GlaxoSmithKline plc, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals plc, Fresenius Kabi AG, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd.

North America was the largest region in the diabetic kidney disease market in 2023. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of diabetic kidney disease are associated with both type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition characterized by minimal or no insulin production by the pancreas. This deficiency leads to elevated blood sugar levels, causing damage to the nephrons and renal blood vessels. Managing blood sugar levels in type 1 diabetes often requires daily insulin injections. Treatment for diabetic kidney disease includes interventions such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other medical approaches provided in facilities such as hospitals, homecare, specialty centers, and more.

The diabetic kidney disease market research report is one of a series of new reports that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Diabetic Kidney Disease Market Characteristics3. Diabetic Kidney Disease Market Trends and Strategies
4. Diabetic Kidney Disease Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Diabetic Kidney Disease Market Size and Growth
5.1. Global Diabetic Kidney Disease Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Diabetic Kidney Disease Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Diabetic Kidney Disease Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Diabetic Kidney Disease Market Segmentation
6.1. Global Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type 1 Diabetes
  • Type 2 Diabetes
6.2. Global Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Angiotensin Receptor Blockers (Arbs)
  • Angiotensin-Converting Enzyme (Ace) Inhibitors
  • Antioxidant Inflammation Modulator
  • Calcium Channel Blockers
  • Other Treatments
6.3. Global Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End Users
7. Diabetic Kidney Disease Market Regional and Country Analysis
7.1. Global Diabetic Kidney Disease Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Diabetic Kidney Disease Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Diabetic Kidney Disease Market
8.1. Asia-Pacific Diabetic Kidney Disease Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Diabetic Kidney Disease Market
9.1. China Diabetic Kidney Disease Market Overview
9.2. China Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Diabetic Kidney Disease Market
10.1. India Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Diabetic Kidney Disease Market
11.1. Japan Diabetic Kidney Disease Market Overview
11.2. Japan Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Diabetic Kidney Disease Market
12.1. Australia Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Diabetic Kidney Disease Market
13.1. Indonesia Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Diabetic Kidney Disease Market
14.1. South Korea Diabetic Kidney Disease Market Overview
14.2. South Korea Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Diabetic Kidney Disease Market
15.1. Western Europe Diabetic Kidney Disease Market Overview
15.2. Western Europe Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Diabetic Kidney Disease Market
16.1. UK Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Diabetic Kidney Disease Market
17.1. Germany Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Diabetic Kidney Disease Market
18.1. France Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Diabetic Kidney Disease Market
19.1. Italy Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Diabetic Kidney Disease Market
20.1. Spain Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Diabetic Kidney Disease Market
21.1. Eastern Europe Diabetic Kidney Disease Market Overview
21.2. Eastern Europe Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Diabetic Kidney Disease Market
22.1. Russia Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Diabetic Kidney Disease Market
23.1. North America Diabetic Kidney Disease Market Overview
23.2. North America Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Diabetic Kidney Disease Market
24.1. USA Diabetic Kidney Disease Market Overview
24.2. USA Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Diabetic Kidney Disease Market
25.1. Canada Diabetic Kidney Disease Market Overview
25.2. Canada Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Diabetic Kidney Disease Market
26.1. South America Diabetic Kidney Disease Market Overview
26.2. South America Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Diabetic Kidney Disease Market
27.1. Brazil Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Diabetic Kidney Disease Market
28.1. Middle East Diabetic Kidney Disease Market Overview
28.2. Middle East Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Diabetic Kidney Disease Market
29.1. Africa Diabetic Kidney Disease Market Overview
29.2. Africa Diabetic Kidney Disease Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Diabetic Kidney Disease Market, Segmentation by Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Diabetic Kidney Disease Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Diabetic Kidney Disease Market Competitive Landscape and Company Profiles
30.1. Diabetic Kidney Disease Market Competitive Landscape
30.2. Diabetic Kidney Disease Market Company Profiles
30.2.1. AstraZeneca plc
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Pfizer Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Novartis AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Bayer AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Sanofi SA
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Diabetic Kidney Disease Market Competitive Benchmarking32. Global Diabetic Kidney Disease Market Competitive Dashboard33. Key Mergers and Acquisitions in the Diabetic Kidney Disease Market
34. Diabetic Kidney Disease Market Future Outlook and Potential Analysis
34.1 Diabetic Kidney Disease Market in 2028 - Countries Offering Most New Opportunities
34.2 Diabetic Kidney Disease Market in 2028 - Segments Offering Most New Opportunities
34.3 Diabetic Kidney Disease Market in 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic and Forecast Inflation Rates
35.4. Research Inquiries
35.5. About the Analyst
35.6. Copyright and Disclaimer

Executive Summary

Diabetic Kidney Disease Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for diabetic kidney disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Type 1 Diabetes; Type 2 Diabetes

2) By Treatment: Angiotensin Receptor Blockers (Arbs); Angiotensin-Converting Enzyme (Ace) Inhibitors; Antioxidant Inflammation Modulator; Calcium Channel Blockers; Other Treatments

3) By End User: Hospitals; Homecare; Specialty Centers; Other End Users

Companies Mentioned: AstraZeneca plc; Pfizer Inc.; Novartis AG; Bayer AG; Sanofi SA

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca plc
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Mylan NV
  • Aurobindo Pharma Ltd.
  • Fresenius SE & Co. KGaA
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Reata Pharmaceuticals Inc.
  • Merck & Co.
  • Mitsubishi Tanabe Pharma Corporation
  • Johnson & Johnson pvt. Ltd.
  • Eli Lilly and Company
  • Allergan Inc.
  • Endo International Inc.
  • GlaxoSmithKline plc
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals plc
  • Fresenius Kabi AG
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Chugai Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd.

Methodology

Loading
LOADING...